RECRUITING

Sensory-Evoked Cortical Gamma Oscillation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.

Official Title

Sensory-Evoked Cortical Gamma Oscillation: Impact on Visual Processing and Cognitive Function in Patients With Alzheimer's Disease

Quick Facts

Study Start:2022-07-01
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05206305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011)
  2. * Fluent and literate in English language
  3. * Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research
  4. * Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results
  1. * Not fluent and literate in English
  2. * Severe dementia
  3. * Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities
  4. * Cardiac pacemakers or any other implants that may not be compatible with MRI
  5. * Cognitively impaired to the point the patient is unable to consent for themselves
  6. * Claustrophobic to the point that medication is required

Contacts and Locations

Study Contact

Roberto Fernandez-Romero, MD
CONTACT
865-305-7242
rfernandez@utmck.edu
Kyle Dean
CONTACT
865-305-2273
kdean1@utmck.edu

Principal Investigator

Roberto Fernandez-Romero, MD
PRINCIPAL_INVESTIGATOR
University of Tennessee Medical Center

Study Locations (Sites)

University of Tennessee Medical Center
Knoxville, Tennessee, 37920
United States

Collaborators and Investigators

Sponsor: University of Tennessee Medical Center

  • Roberto Fernandez-Romero, MD, PRINCIPAL_INVESTIGATOR, University of Tennessee Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-01
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2022-07-01
Study Completion Date2026-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Alzheimer Disease